Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions.
In an attempt to restore immune competence to 12 human immunodeficiency virus-1 (HIV-1)-infected patients, lymphocytes from their HIV-1-uninfected identical twin siblings were cultured in medium supplemented with 5% fetal calf serum (FCS), anti-CD3 antibody, and interleukin-2 (100 IU/mL) for 10 days and then infused into the patients. After multiple infusions, at 6- to 8-week intervals, half of the patients developed arthus-like reactions within 4 to 12 hours of infusion consisting of fever > 39 degrees C, hypotension, rigors, arthralgias, myalgias, headache, and/or malaise. Preinfusion and postinfusion serum samples were evaluated for the presence of antibodies to FCS using double immunodiffusion. All preinfusion serum samples were negative by this method while 8 of the 12 patients developed antibodies to a single component of FCS after two or more infusions of lymphocytes cultured in FCS-supplemented medium. Prick skin testing to standardized beef extract was negative in all patients. There was a correlation between initial CD4 level and the development of antibodies to FCS (median initial CD4 count in FCS antibody positive patients = 362.0/microL v median initial CD4 count of nonresponders = 135.0/microL). There was no correlation with response to recall antigens in delayed-type hypersensitivity testing. We conclude that selected patients were sensitized to a single component of FCS carried on donor lymphocytes, despite thorough washing of the cells before infusion. The development of antibodies to FCS indicates that immune complex formation could have occurred after the cell infusions, resulting in the arthus-like reactions. These observations suggest that the therapeutic use of human lymphocytes cultured in FCS may expose the recipient to immunogenic substances with possible clinical sequelae.
Selvaggi
T A
TA
Immunology Service, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Walker
R E
RE
Fleisher
T A
TA
D000818:Animals; D000910:Antibodies, Heterophile / Q000096:biosynthesis*; D015478:Antigens, Heterophile / Q000276:immunology; D001183:Arthus Reaction / Q000209:etiology* / Q000235:genetics / Q000276:immunology*; D002417:Cattle; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D004200:Diseases in Twins / Q000235:genetics / Q000628:therapy; D005312:Fetal Blood / Q000276:immunology*; D015658:HIV Infections / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology / Q000235:genetics / Q000276:immunology; D007073:Immunoglobulin E / Q000096:biosynthesis; D017710:Lymphocyte Transfusion / Q000009:adverse effects*; D013045:Species Specificity; D014430:Twins, Monozygotic
D000910:Antibodies, Heterophile; D015478:Antigens, Heterophile; D017077:Culture Media, Conditioned; D007073:Immunoglobulin E